ID: h-debate-516516c6941a
Hypothesis

Arginine-Rich DPR Competitive Inhibitors

Designed peptide mimetics that competitively bind to the same cellular targets as pathological arginine-rich DPRs could prevent their interference with normal phase separation processes.
🧬 C9orf72🎯 Composite 0%💱 $0.51▲1.1%proposed
neurodegeneration
EvidenceModerate (50%)📖 0 cit🗣 1 debates 1 support 0 oppose
✓ All Quality Gates Passed
Mechanistic 0.60 (15%) Evidence 0.55 (15%) Novelty 0.60 (12%) Feasibility 0.00 (12%) Impact 0.00 (12%) Druggability 0.00 (10%) Safety 0.00 (8%) Competition 0.00 (6%) Data Avail. 0.00 (5%) Reproducible 0.00 (5%) KG Connect 0.44 (8%) 0.000 composite

🧪 Overview

Designed peptide mimetics that competitively bind to the same cellular targets as pathological arginine-rich DPRs could prevent their interference with normal phase separation processes.

Debate provenance: derived from debate `sess_SDA-2026-04-11-sda-2026-04-01-gap-006` on question: TDP-43 phase separation therapeutics for ALS-FTD. Consensus signal: domain_expert, skeptic, synthesizer, theorist discussed the mechanism terms Arginine-Rich, Competitive, DPR, Inhibitors. Novelty signal: skeptic-discussed-with-qualified-concession.

🧬 Mechanism

🔗 Mechanism from KG for C9orf72

Auto-built from this analysis's top knowledge-graph edges.

graph TD
    C9orf72["C9orf72"] -->|produces pathologi| DPR_proteins["DPR_proteins"]
    C9orf72_1["C9orf72"] -->|risk factor for| ALS_FTD["ALS/FTD"]
    C9orf72_DPR_neutralizing_["C9orf72 DPR neutralizing agents"] -->|prevents| TDP_43_phase_separation_d["TDP-43 phase separation disruption"]
    C9ORF72["C9ORF72"] -->|increases risk| Familial_ALS["Familial ALS"]
    C9ORF72_2["C9ORF72"] -->|co discussed| HSP70["HSP70"]
    C9ORF72_3["C9ORF72"] -->|co discussed| TAU["TAU"]
    style C9orf72 fill:#ce93d8,stroke:#333,color:#000
    style DPR_proteins fill:#4fc3f7,stroke:#333,color:#000
    style C9orf72_1 fill:#ce93d8,stroke:#333,color:#000
    style ALS_FTD fill:#ef5350,stroke:#333,color:#000
    style C9orf72_DPR_neutralizing_ fill:#4fc3f7,stroke:#333,color:#000
    style TDP_43_phase_separation_d fill:#4fc3f7,stroke:#333,color:#000
    style C9ORF72 fill:#ce93d8,stroke:#333,color:#000
    style Familial_ALS fill:#ef5350,stroke:#333,color:#000
    style C9ORF72_2 fill:#ce93d8,stroke:#333,color:#000
    style HSP70 fill:#ce93d8,stroke:#333,color:#000
    style C9ORF72_3 fill:#ce93d8,stroke:#333,color:#000
    style TAU fill:#ce93d8,stroke:#333,color:#000

⚖️ Evidence

📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — C9ORF72

No curated PDB or AlphaFold mapping for C9ORF72 yet. Search RCSB →

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for C9orf72 →

No DepMap CRISPR Chronos data found for C9orf72.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0002
Events (7d)
1
Price History
▲1.1%

💾 Resource Usage

LLM Tokens
51,518
$0.3091
Total Cost
$0.3091
Metadatasource: v1_phase_c_backfill · origin_type: debate_round_mining
sourcev1_phase_c_backfill
origin_typedebate_round_mining
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.